Anthony J. Perissinotti

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis

Marisa H. Miceli, Anthony J. Perissinotti, Carol A. Kauffman et al. · Mycoses · 2015 · 67 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Risk factors for subtherapeutic levels of posaconazole tablet

Laura Tang, Bernard L. Marini, Lydia L. Benitez et al. · Journal of Antimicrobial Chemotherapy · 2017 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

The role of trastuzumab in the management of salivary ductal carcinomas.

Anthony J. Perissinotti, Matthew Pierce, Makala B. Pace et al. · PubMed · 2013 · 39 citations

Medicine, Oncology, Pharmacology +17

Risk factors and impact of Clostridium difficile recurrence on haematology patients

Gianni B. Scappaticci, Anthony J. Perissinotti, Jerod Nagel et al. · Journal of Antimicrobial Chemotherapy · 2017 · 39 citations · Full text

Veterinary Medicine, Infectious Diseases, Chemotherapy +12

Multicentre study of posaconazole delayed-release tablet serum level and association with hepatotoxicity and QTc prolongation

Natasha N. Pettit, Marisa H. Miceli, Christina G. Rivera et al. · Journal of Antimicrobial Chemotherapy · 2017 · 37 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15